PFO
MRNS

Pathstone Family Office’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Pathstone Family Office’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-699
Closed -$9K – 1368
2020
Q3 		$9K Buy
+699
New +$6.03K ﹤0.01% 622

Other funds holding MRNS

LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Pathstone Family Office's MRNS Position: Q4 2020 in Review

Pathstone Family Office sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2020, closing a stake of 699 shares — an estimated $9K sold.

Pathstone Family Office first reported a position in MRNS in Q3 2020 and held it in 1 quarter. The position peaked at $9K in Q3 2020. 88 funds tracked by Wall St. Rank hold MRNS as of Q4 2020.

  • Pathstone Family Office reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2020 after selling out during the quarter.
  • Pathstone Family Office sold 699 Marinus Pharmaceuticals, Inc shares in Q4 2020, an estimated $9K.
  • Pathstone Family Office first reported a position in Marinus Pharmaceuticals, Inc in Q3 2020 and held it in 1 quarter.
  • Pathstone Family Office's Marinus Pharmaceuticals, Inc position peaked at $9K in Q3 2020.
  • 88 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2020.

Based on Pathstone Family Office's 13F filing for Q4 2020, filed 16 Feb 2021.